Clinical Trials
2.0k
Trial Phases
5 Phases
Drug Approvals
262
Drug Approvals
Guselkumab Injection (Intravenous Infusion)
- Product Name
- 特诺雅达
- Approval Number
- 国药准字SJ20250006
- Approval Date
- Feb 20, 2025
Ustekinumab Injection(Intravenous Infusion)
- Product Name
- 喜达诺
- Approval Number
- 国药准字SJ20200005
- Approval Date
- Jan 15, 2025
Niraparib Tosylate and Abiraterone Acetate Tablets
- Product Name
- 尼拉帕利阿比特龙片
- Approval Number
- 国药准字HJ20240110
- Approval Date
- Oct 16, 2024
Niraparib Tosylate and Abiraterone Acetate Tablets
- Product Name
- 尼拉帕利阿比特龙片
- Approval Number
- 国药准字HJ20240111
- Approval Date
- Oct 16, 2024
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (1622 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 93
- Registration Number
- NCT04940039
- Locations
- 🇷🇼
University Teaching Hospital of Butare(CHUB), Butare, Rwanda
🇷🇼Kibuye Referral Hospital, Kibuye, Rwanda
🇷🇼CARAES Ndera Neuro-Psychiatric Hospital, Kigali, Rwanda
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 676
- Registration Number
- NCT04338321
- Locations
- 🇦🇷
FunDaMos, Ciudad Autonoma de Buenos Aires, Argentina
🇦🇷Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷CEN Consultorios Especializados en Neurociencias, Cordoba, Argentina
A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 29
- Registration Number
- NCT03947814
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪APEX GmbH, Munchen, Germany
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Registration Number
- NCT03852160
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 880
- Registration Number
- NCT03818035
- Locations
- 🇩🇪
Universitatsklinikum Dusseldorf, Düsseldorf, Germany
🇫🇷Hopital Prive d'Antony, Antony, France
🇫🇷Centre Hospitalier d'Auxerre, Auxerre, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
EC Approves Amivantamab Plus Lazertinib for First-Line EGFR-Mutated NSCLC
• The European Commission has approved amivantamab plus lazertinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). • The approval is based on the Phase 3 MARIPOSA trial, which showed superior progression-free survival compared to osimertinib. • The combination therapy reduced the risk of disease progression or death by 30% compared to osimertinib monotherapy. • Common adverse events were manageable and primarily Grade 1 or 2, supporting the combination's safety profile.
CHMP Recommends Subcutaneous Amivantamab for EGFR-Mutated NSCLC Treatment
The CHMP has recommended subcutaneous amivantamab with lazertinib for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
RYBREVANT Plus Chemotherapy Shows Positive Survival Trend in EGFR-Mutated Lung Cancer
Updated results from the Phase 3 MARIPOSA-2 study show RYBREVANT plus chemotherapy demonstrates a favorable trend toward improved overall survival.